Call Karen if you are interested in the AE37/GP2 clinical trial!
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
http://www.clinicaltrials.gov/ct2/show/NCT00524277?term=her2%2Fneu+vaccine&recr=Open&rank =5 Karen Escamilla, RN, BSN, CCRP Regional Clinical Manager Cancer Vaccine Development Program San Antonio Military Medical Center General Surgery Clinic 3551 Roger Brooke Drive Ft. Sam Houston, TX 78234 210-916-4837 Email: karen.l.escamilla.ctr@us.army.mil |
All times are GMT -7. The time now is 09:36 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021